Artrya (ASX:AYA) entered a five-year commercial agreement with Cone Health, for the use of the Salix cloud platform for the assessment and management of coronary artery disease, according to a Tuesday Australian bourse filing.
The deal has a minimum value of $450,000, with additional per-scan revenue for the use of Salix's plaque module, the company said.